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The Euro-Balance Trial: The effect of a new biocompatible peri-
toneal dialysis fluid (balance) on the peritoneal membrane.
Background. Although peritoneal dialysis (PD) is a widely
accepted form of renal replacement therapy (RRT), concerns
remain regarding the bioincompatible nature of standard PD
fluid. In order to evaluate whether a newly formulated fluid
of neutral pH, and containing low levels of glucose degrada-
tion products (GDP), resulted in improved in vivo biocompat-
ibility, it was compared in a clinical study to a standard PD
fluid.
Methods. In a multicenter, open, randomized, prospective
study with a crossover design and parallel arms, a conven-
tional, acidic, lactate-buffered fluid (SPDF) was compared
with a pH neutral, lactate-buffered, low GDP fluid (balance).
Overnight effluent was collected and assayed for cancer anti-
gen 125 (CA125), hyaluronic acid (HA), procollagen peptide
(PICP), vascular endothelial growth factor (VEGF), and tumor
necrosis factor alpha (TNFa). Serum samples were assayed for
circulating advanced glycosylation end products (AGE), Ne-
(carboxymethyl)lysine (CML), and imidazolone. Clinical end
points were residual renal function (RRF), adequacy of dialy-
sis, ultrafiltration, and peritoneal membrane function. Eighty-
six patients were randomized to either group I starting with
SPDF for 12 weeks (Phase I), then switching to “balance” for
12 weeks (Phase II), or group II, which was treated vice versa.
Seventy-one patients completed the study with data suitable for
entry into the per protocol analysis. Effluent and serum samples,
together with peritoneal function tests and adequacy measure-
ments, were undertaken at study centers on three occasions
during the study: after the four-week run-in period, after Phase
I, and again after Phase II.
Results. In patients treated with balance there were sig-
nificantly higher effluent levels of CA125 and PICP in both
arms of the study. Conversely, levels of HA were lower in pa-
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tients exposed to balance, while there was no change in the
levels of either VEGF or TNFa. Serum CML and imidazolone
levels fell significantly in balance-treated patients. Renal urea
and creatinine clearances were higher in both treatment arms af-
ter patients were exposed to balance. Urine volume was higher
in patients exposed to balance. In contrast, peritoneal ultrafil-
tration was higher in patients on SPDF. When anuric patients
were analyzed as a subgroup, there was no significant differ-
ence in peritoneal transport characteristics or in ultrafiltration
on either fluid. There were no changes in peritonitis incidence
on either solution.
Conclusion. This study indicates that the use of balance,
a neutral pH, low GDP fluid, is accompanied by a signifi-
cant improvement in effluent markers of peritoneal membrane
integrity and significantly decreased circulating AGE levels.
Clinical parameters suggest an improvement in residual renal
function on balance, with an accompanying decrease in peri-
toneal ultrafiltration. It would appear that balance solution re-
sults in an improvement in local peritoneal homeostasis, as well
as having a positive impact on systemic parameters, including
circulating AGE and residual renal function.
Peritoneal dialysis (PD) is now established as a form
of renal replacement therapy (RRT) comparable with
hemodialysis when used as a first choice therapy [1–3].
Despite this, long-term PD is associated with structural
membrane changes that are believed to contribute to al-
terations in solute transport and loss of ultrafiltration
[4, 5]. Although the factors responsible for these alter-
ations remain to be determined, it is widely accepted that
the bioincompatible nature of conventional PD solutions
(low pH, lactate concentration, and the long-term ex-
posure to high concentrations of glucose) contributes to
changes in membrane structure and function [6]. Based
on measurements of both inflammatory cell function dur-
ing PD, and measurement of markers of mesothelial cell
function in peritoneal effluent, the data suggest that peri-
toneal homeostasis is adversely affected by the adminis-
tration of conventional PD solutions [7, 8].
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Fig. 1. Flow diagram of the study design. Visit 1, II, and III indicate
clinic visits at the end of the 4-week run-in phase, and after the two
12-week trial periods. SPDF, standard peritoneal dialysis fluid.
More recently, emphasis has been focused on the im-
pact of glucose exposure and its possible relationship to
changes in the peritoneal membrane’s dialytic function
[9, 10]. This relationship may be related to a direct role of
glucose [11, 12], to the degradation products of glucose
(GDP) generated during the heat sterilization process
[13–15], or to the role of either as a substrate for nonenzy-
matic glycosylation of the tissues [10, 16]. GDP have been
shown, in in vitro studies, to be cytotoxic, to modulate cell
proliferation, cell migration, to retard remesothelializa-
tion, and to down-regulate cytokine and growth factor
synthesis [13, 17–20]. In vivo studies have highlighted
potential adverse effects of GDP on leukocyte recruit-
ment [21, 22], and clinical observations have linked GDP
to infusion pain and impaired ultrafiltration capacity
[23].
A further potential problem is that GDP, particularly 3-
deoxyglucosone (3-DG) and methylglyoxal (MGO), ac-
celerates the development of advanced glycosylation end
products [24–27]. GDP have even been demonstrated to
be more potent catalysts of AGE formation than glucose
itself [25]. This is of particular relevance to PD because
the deposition of AGE in the peritoneal membrane cor-
relates with the development of peritoneal fibrosis [10]
and with VEGF-mediated changes in the peritoneal vas-
culature, which may contribute to loss of ultrafiltration
[12]. Furthermore, the presence of GDP in the peritoneal
fluid may contribute to the generation of circulating car-
bonyl compounds, resulting in the acceleration of sys-
temic AGE formation [28].
The aim of the current project was to compare the
impact of a new, neutral pH, low GDP PD solution
compared with conventional solutions on important
biochemical and clinical parameters. Our data suggest
that continuous dialysis with balance alters effluent mark-
ers towards a more physiologic response, reduces circu-
lating AGE levels, and improves residual renal function.
METHODS
Study design
This was a multicenter, open, randomized, prospective
study with a crossover design and parallel arms compar-
ing a standard PD solutions (SPDF) with a new, neutral
pH, low GDP solution (balance). All patients underwent
an initial four-week run-in phase on SPDF (Stay-safe;
Fresenius Medical Care, Bad Homburg, Germany) with
1.5%, 2.3%, or 4.25% glucose as appropriate. After the
run-in phase, patients were randomized (1:1) to either
12 weeks of treatment with SPDF (group I) or 12 weeks of
treatment with balance (Fresenius Medical Care) (group
II)—treatment phase 1. Patients then switched therapies
and underwent a further 12 weeks’ treatment with bal-
ance or SPDF—treatment phase 2 (Fig. 1).
The primary end point was the concentration of CA125
in the dialysis effluent. Secondary end points were (1) bio-
chemical: HA, TNFa, VEGF, PICP, (2) markers of AGE:
CML and imidazolone in serum and in dialysis effluent,
and (3) clinical: adequacy of dialysis (creatinine clearance
and Kt/V), ultrafiltration, urine volume, peritoneal mem-
brane function (D/P creatinine at 4 hours), routine blood
chemistry, abdominal pain, and tolerability.
Study population
This study was undertaken in 22 centers in 11 European
countries. A total of 96 patients were registered for the
study, 10 of which were excluded before visit 1 because
of screening failures. The remaining 86 patients entered
the study phase, randomized equally between groups I
and II. Thirteen patients prematurely discontinued treat-
ment. During treatment with SPDF, 8 patients discontin-
ued [peritonitis (3), transplantation (2), UF decline (1),
abdominal leakage (1), vasculitis (1)]. During treatment
with balance, 5 patients discontinued [peritonitis (1), UF
decline (2), dyspnoe (1), switch to APD (1)]. For reasons
of protocol deviations (peritonitis within 4 weeks before
laboratory measurements), out of the remaining 73 pa-
tients to complete the trial, 71 with complete measure-
ments were included in the per protocol analysis. For the
primary end point, CA125 levels and the effluent mark-
ers, samples were analyzed from 71 per protocol patients
(group I, N = 36; group II, N = 35). CML and imida-
zolone dialysate and serum levels were measured in a
subgroup of patients from the UK, Poland, and Germany:
(group I, N = 20; group II, N = 11). Complete clinical
data were available for 67 patients. The clinical outcomes
were analyzed for the group as a whole (group I, N = 36;
group II, N = 35), and following division of the pa-
tients into two subgroups: (1) anuric patients—those who
passed ≤200 mL urine per 24 hours (group I, N = 11;
group II, N = 8); and (2) patients with residual urine
output—those who passed >200 mL of urine per 24 hours
(group I, N = 25, group II, N = 23).
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Table 1. Baseline demographic variables for the per protocol (PP)
group, reported as median interquartile range (IQR) unless otherwise
stated
Group I Group II P value
Gender M:F 19:17 23:12 ns
Age years 61 (46–68) 57 (51–71) ns
Weight kg 70 (58.9–80.0) 74.5 (63.8–81.5) ns
Height m 1.69 (1.63–1.74) 1.68 (1.63–1.76) ns
Diagnosis
Diabetic 11 (30.6%) 11 (31.4%) ns
nephropathy
ADPKD 4 (11.1%) 3 (8.6%) ns
Vascular 2 (5.6%) 6 (17.1%) ns
nephropathy
Glomerulonephritis 7 (19.4%) 0 (0%) 0.0113
Interstitial nephritis 1 (2.8%) 4 (11.4%) ns
Nephrosclerosis 2 (5.6%) 2 (5.7%) ns
Hypertensive 1 (2.8%) 2 (5.7%) ns
nephropathy
Other 8 (22.2%) 7 (20%) ns
Duration of PD 10 (4–15) 6 (3–14) ns
months
Renal urea clearance 3.32 (1.09–5.32) 2.76 (1.08–4.98) ns
L/day
Renal creatinine 4.56 (1.93–7.08) 3.97 (2.5–7.9) ns
clearance L/day
Urine volume 698 (137.5–1550) 700 (340–1090) ns
mL/24hours
Approval for the study was obtained from local ethics
committees in each country, and all patients gave written
informed consent before study entry. Patients included
in the study (Table 1) had been established on PD for
between 3 to 18 months using conventional PD solutions.
Baseline characteristics and time on PD at commence-
ment were not different except for an over-representation
of glomerulonephritis in group I (P = 0.0136).
Study protocol
Participants had blood and effluent sampling, peri-
toneal function tests, and adequacy measurements un-
dertaken at the study centers on 3 occasions during the
study: after the four-week run in period, after 12 weeks
on either conventional lactate-buffered PDF (SPDF) or
balance at the end of Phase 1, and again after 12 weeks
on the alternative treatment at the end of Phase 2. The
sampling window was ± 7 days from the scheduled date,
unless patients had peritonitis, when they were excluded
from sampling until at least four weeks after clinical
resolution.
Effluent markers
At the end of the run-in period, and at the end of
treatment Phases 1 and 2, timed effluent collections were
undertaken. Fifty milliliters of effluent were collected
from a timed 2.3% overnight (12-hour) drain, filtered
(0.2 l filter), and aliquoted into 3 mL samples. Samples
were stored at −20◦C or −70◦C before assay in a single
laboratory. All effluent samples were archived centrally,
and were analyzed in a blinded manner.
Cancer antigen 125
CA125 (Interlab, Heidelberg, Germany) was mea-
sured using an electrochemiluminescence immunoassay
(Elecsys 2010; Roche Diagnostics, GmbH, Mannheim,
Germany until February 2, 2002, and Modular E170;
Roche Diagnostics, from February 18, 2002), as per man-
ufacturer’s instructions. Seven samples were measured
using Modular E170. The minimum detectable concen-
tration was 0.60 U/mL for Elecsys 2010, and 1.1 U/mL for
E170. The coefficient of variation for the total precision
was between 1.7–2.5 and 2.5–4.2, respectively, depending
on the concentration of the human serum (7.8 U/mL to
70.8 U/mL for Elecsys 2010, and 21.1 U/mL to 1816 U/mL
for Modular E170).
Advanced glycation end products (AGE)
CML and imidazolone in serum and dialysate were
measured at The Institute of Pharmacy and Food
Chemistry, University Erlangen-Nu¨rnberg. A competi-
tive enzyme-linked immunosorbent assay (ELISA) using
the CML-specific monoclonal antibody 4G9 measured
CML in both serum and dialysate. This research assay
was provided by Roche Diagnostics GmbH, Penzberg,
Germany [29]. The minimum detectable concentration
in the assay was 3.9 ng/mL, and the coefficient of varia-
tion for interassay and intra-assay variability was between
8.3% and 13.4% and 0.26% to 2.7%, respectively.
Imidazolone was measured in both serum and dialysate
by ELISA using a noncommercial monoclonal antibody,
which is specific for imidazolone [30]. Imidazolone-HSA,
prepared by the reaction of HSA with 3-DG, was used as
a standard. The minimum detectable concentration in the
assay was 0.6 lg/mL, and the coefficient of variation for
interassay and intra-assay variability was between 7.8%
and 12.5% and 0.1% to 2.4%, respectively.
Remaining markers were measured at the Institute of
Nephrology, University of Wales College of Medicine,
Cardiff Wales, UK.
Hyaluronic acid
HA was measured by commercial ELISA (hyaluronic
acid “Chugai” quantitative test kit; TSC Biological Ltd.,
Bucks, UK) according to the manufacturer’s instructions.
The minimum detectable concentration in the assay was
10 ng/mL, and the coefficient of variation for interassay
and intra-assay variability was between 3.6% and 4.2%
and 5.7% to 7.0%, respectively [31].
Procollagen I peptides
PICP were measured by commercial ELISA (Type I
Procollagen, PICP; Radioimmunoassay Kit, Orion Diag-
nostica, Espoo, Finland) according to the manufacturer’s
instructions. The minimum detectable concentration in
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the assay was 5.1 ng/mL, and the coefficient of varia-
tion for interassay and intra-assay variability was between
4.8% and 10.4% and 4.8% to 9.4%, respectively.
Vascular endothelial growth factor
VEGF was measured by commercial ELISA (human
VEGF immunoassay; R&D Systems, Inc., Abingdon,
UK) according to the manufacturer’s instructions. The
minimum detectable concentration in the assay was
5 pg/mL, and the coefficient of variation for interassay
and intra-assay variability was between 5.0% and 8.5%
and 3.5% to 6.5%, respectively.
Tumor necrosis factor alpha
TNFa was measured by commercial ELISA (human
TNFa immunoassay; R&D Systems, Inc.) according to
the manufacturer’s instructions. The minimum detectable
concentration in the assay was 4.4 pg/mL, and the co-
efficient of variation for interassay and intra-assay vari-
ability was between 6.8% and 8.7% and 4.4% to 5.3%,
respectively.
Peritoneal membrane function, dialysis adequacy
measurement, and residual renal function
Peritoneal membrane function was measured using the
standard peritoneal function test (PFT) procedure with
the QA (quality assurance) bag [32]. Two liters of 2.3%
glucose were infused (SPDF or balance, dependent on
treatment arm and stage of the protocol). Samples of ef-
fluent were taken at time points 0, 120, and 240 minutes,
and a blood sample was drawn during the dwell of the
QA exchange. The ratio of dialysate to plasma creatinine
at four hours (D/P creatinine) was calculated.
Dialysis adequacy was expressed as Kt/Vurea and crea-
tinine clearance (L/wk/1.73m2).
Solute clearance was measured by collecting all the
used dialysate effluent over a 24-hour period and tak-
ing a plasma sample during the QA exchange period.
The concentrations of urea and creatinine were measured
in each single bag and in the plasma sample. Using the
24-hour volume, the 24-hour clearance was obtained,
which was then multiplied to give a weekly clearance.
Creatinine clearance was standardized to a body surface
area of 1.73 m2, while urea clearance was expressed as
Kt/V, where Kt is the weekly clearance of urea, and V the
volume of distribution.
Residual renal function was assessed by collecting all
the urine output over the same 24-hour period as the
dialysate collection, measuring the urea and creatinine
concentrations, and recording the urine volume. Renal
creatinine clearance was corrected using the formula (C
urea + C creatinine)/2. Individuals with daily urine vol-











































Fig. 2. Box plots of effluent cancer antigen 125 (CA125, U/mL) for
standard peritoneal fluid (SPDF) and balance in group I and II. CA125
levels were significantly higher in both treatment arms following 12
weeks of treatment with balance. For detailed description of box plots
see Methods.
Statistical analysis
Statistical analysis was performed using SAS ver-
sion 8.2 (Cary, NC, USA). Data that were not normally
distributed were analyzed using nonparametric statistics
(Wilcoxon Mann-Whitney for two related samples), with
differences considered to be biologically significant if re-
ciprocal and statistically significant differences were seen
in both arms of the study. Unless otherwise stated, re-
sults are reported as median (range). Within all box plots,
the line within the box represents median values. The
box represents 50% of the values (the 25th and 75th per-
centiles), with the bars representing the highest and low-
est values, excluding outliers (values between 1.5 and 3
box lengths from the upper and lower edges of the box,
the box length being the interquartile range) and extreme
values (more than 3 box lengths from the upper and lower
edges of the box, the box length being the interquartile
range). Outlying values are represented by the symbol o
and extreme values by the symbol ∗.
The run-in period of 4 weeks was not used for analysis
purposes, statistical comparisons being made only at the
end of each 12-week treatment phase.
RESULTS
Effluent cancer antigen 125 levels
Effluent CA125 levels were significantly increased in
patients treated with balance in both arms of the study
(Fig. 2).
CA125 levels (U/mL) in group I were 12 (3.93 to
85) U/mL after 3 months of SPDF, rising to 48 (14 to
373) U/mL after 3 months balance (N = 35, P < 0.0001).
In group II, levels were 38 (3.42 to 122) U/mL on balance,
falling to 13 (4 to 44) after 3 months on SPDF (N = 36,
P < 0.0001).





































Fig. 3. Box plots of effluent hyaluronic acid (HA, ng/mL) for standard
peritoneal fluid (SPDF) and balance in group I and II. HA levels were
significantly lower in both treatment arms following 12 weeks of treat-







































Fig. 4. Box plots of effluent procollagen I peptides (PICP, ng/mL) for
standard peritoneal fluid (SPDF) and balance in group I and II. PICP
levels were significantly higher in both treatment arms following 12
weeks of treatment with balance. For detailed description of box plots
see Methods.
Effluent hyaluronic acid levels
HA levels were significantly lower in patients dialyzed
with balance compared with SPDF in both arms of the
study (Fig. 3). HA levels in group I were 333.5 (60.16
to 1121.88) ng/mL after 3 months treatment with SPDF,
decreasing to 235.4 (58.08 to 2043.6) ng/mL after 3 months
treatment with balance (N = 35, P = 0.009).
In group II, levels were 218.34 (47.1 to 1102.9) ng/mL
after 3 months on balance, and increased to 263.7 (77.95
to 839) ng/mL after 3 months of SPDF use (N = 36, P =
0.016).
Effluent VEGF and TNFa levels
VEGF and TNFa levels in effluent were not different
irrespective of treatment. In group I (N = 35), VEGF
levels were 36.9 (17.4 to 73.9) pg/mL after 3 months of
SPDF treatment and 33.3 (18.8 to 347.5) pg/mL after
3 months of balance treatment. In group II, (N = 36),















































Fig. 5. Box plots of serum Ne-(carboxymethyl)lysine (CML, ng/mL)
for standard peritoneal fluid (SPDF) and balance in group I and II.
CML levels were significantly lower following 12 weeks of treatment
with balance. For detailed description of box plots see Methods.
balance treatment and 35.9 (14.39 to 68.88) pg/mL after
3 months on SPDF.
In group I (N = 35) (SPDF to balance), TNFa levels
were 4.3 (3.04 to 7.91) pg/mL after 3 months of SPDF
treatment and 3.98 (2.92 to 5.52) pg/mL after 3 months
on balance treatment. In group II (N = 36), levels were
4.4 (2.79 to 5.94) pg/mL after 3 months on balance and
4.14 (2.83 to 5.61) pg/mL after 3 months on SPDF.
Effluent procollagen I peptide levels
PICP levels were statistically significantly higher in pa-
tients treated with balance in groups I and II (Fig. 4).
PICP levels (ng/mL) in group I were 304.5 (38.2 to
989.6) ng/mL after 3 months use of SPDF and 374.9 (91.8
to 1686.4) ng/mL after 3 months on balance (N = 35,
P = 0.021). In group II, levels were 372.04 (65.7 to
1458.2) ng/mL after 3 months on balance, and fell to 204.3
(45.6 to 986.4) ng/mL after 3 months on SPDF (N = 36,
P = 0.001).
Serum and dialysate CML and imidazolone levels
Serum CML levels measured in serum were signifi-
cantly lower in patients treated with balance in both arms
of the study.
In group I, serum CML levels were 318.2 (189.5
to 522.3) ng/mL after 3 months use of SPDF and
279.35 (165.5 to 483.9) ng/mL after 3 months of balance
treatment (N = 20, P = 0.021). In group II, levels were
259.82 (160.4 to 410) ng/mL after 3 months on balance and
341.69 (203.7 to 459.6) ng/mL after 3 months on SPDF
(N = 11, P = 0.018) (Fig. 5).
Statistically significant differences were also demon-
strated in serum imidazolone levels in both arms of the
study. Serum imidazolone levels (lg/mL) in group I were
11.83 (8.79 to 17.33) lg/mL after 3 months use of SPDF
















































Fig. 6. Box plots of serum imidazolone (lg/mL) for standard peritoneal
fluid (SPDF) and balance in group I and II. Imidazolone levels were
significantly lower following 12 weeks of treatment with balance. For
detailed description of box plots see Methods.
and 9.93 (6.75 to 19.9) lg/mL after 3 months on balance
(N = 20, P = 0.018). In group II, levels were 11.81 (6.99 to
19.69) lg/mL after 3 months on balance and 17.54 (9.41
to 19.96) lg/mL after 3 months on SPDF (N = 11, P =
0.015) (Fig. 6).
In dialysis effluent, no differences could be demon-
strated in CML or in imidazolone levels in either treat-
ment arm (data not shown).
Dialysis adequacy
Urea, creatinine clearance, and peritoneal transport
characteristics were measured at the end of the run-in
period and at the end of each 12-week treatment period
with either balance or SPDF. No differences could be
demonstrated in peritoneal urea clearance or peritoneal
creatinine clearance on SPDF, or balance in either treat-
ment arm (Table 2). Renal urea and creatinine clearances
were higher in both treatment arms after patients had un-
dergone 3 months treatment with balance.
In group I, renal urea clearance rose from 3.8 (0.02
to 19.85) L/day on SPDF to 3.9 (0.05 to 26.9) L/day on
balance, P = 0.021, while renal creatinine clearance rose
from 4.9 (0.09 to 16.4) L/day on SPDF to 5.2 (0.05 to
13.03) L/day on balance (P = 0.09). In group II, renal urea
clearance fell from 3.7 (0.66 to 14.09) L/day on balance to
2.7 (0.25 to 12.23) L/day on SPDF, P = 0.007, while renal
creatinine clearance fell from 4.6 (1.02 to 20.9) L/day on
balance to 3.5 (0.38 to 14.66) L/day on SPDF (P = 0.005).
Kt/V and creatinine clearance in group I patients
showed no difference, whether patients had received
3 months treatment with SPDF or balance. In group II,
Kt/V was 2.32 (1.66 to 3.81) on balance, falling to 2.21
(1.43 to 3.49) on SPDF (P = 0.031). Total creatinine clear-
ance was 75.4 (45.3 to 172.04) L/wk/1.73m2 on balance,
falling to 67.1 (42.3 to 121.3) L/wk/1.73m2 on SPDF (P =
0.001).
Peritoneal function
Dialysate-plasma creatinine (D/P creatinine) ratios
were higher in both groups I and II when patients were
on balance. In group I, D/P creatinine was 0.59 (0.35 to
0.80) on SPDF, rising to 0.63 (0.34 to 0.89) on balance
(P = 0.008). The reciprocal change was seen in group II
patients, in which D/P creatinine was 0.60 (0.38 to 0.80)
on balance, falling to 0.56 (0.42 to 0.80) on SPDF (P =
0.0003).
Urine volume, ultrafiltration, and weight
Urine volume (UV) was higher when patients were
treated with balance, but reached statistical significance
only in group II patients, where urine volume fell from
919 (108 to 2000) mL/day on balance to 660 (100 to
2260) mL/day on SPDF (P = 0.023).
Ultrafiltration (UF) was lower in both groups after
treatment with balance. In group I patients, ultrafil-
tration (mL) over 24 hours fell from 1350 (−600 to
2350) mL on SPDF to 995 (−500 to 1950) mL on bal-
ance, (P = 0.0003). In group II, ultrafiltration rose from
1025 (464 to 1915) mL on balance to 1185 (0 to 2385) mL
on SPDF (P = 0.026).
No differences in body weight could be demonstrated
between either treatment group.
Anuric patients
Eleven patients were identified in group I and eight
patients in group II who passed 200 mL of urine or less
per day. Analysis of clinical parameters was carried out
in this subgroup of anuric patients.
Kt/V and creatinine clearance showed no differences
in either group after treatment with SPDF or balance
(Table 3). Nor could any differences be demonstrated in
D/P creatinine in either group after treatment with SPDF
or balance. Ultrafiltration and body weight did not change
on either treatment in groups I or II.
Safety parameters, side effects
No differences within groups and between groups were
recorded for any other parameter (e.g., ionized calcium,
phosphate, potassium, albumin, and hemoglobin). No un-
expected side effects were observed during the study. The
rate of peritonitis with balance was comparable with the
rate of peritonitis using SPDF: using SPDF there was
1 episode of peritonitis every 26.6 patient-months, and
using balance there was 1 episode of peritonitis every
25.6 patient-months. When patients were using balance
there were neither significant changes in blood pres-
sure (either systolic or diastolic) nor was there a change
in heart rate. Inflow pain was reported similarly infre-
quently in both groups.
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Table 2. Dialysis adequacy and peritoneal transport in all patients
Group 1 Group 1 Group 2 Group 2
SPDF balance balance SPDF
(N = 36) (N = 36) P value (N = 35) (N = 35) P value
P Urea Cl L/day 8.1 (4.9–11.23) 7.8 (5.4–10.3) 0.237 8.2 (0.92–9.88) 8.4 (6.4–9.97) 0.220
U Urea Cl L/day 3.8 (1.5–4.5) 3.9 (2.2–6.1) 0.022 3.7 (1.8–6.0) 2.7 (1.3–4.0) 0.007
Kt/V 2.23 (1.96–2.41) 2.33 (2.03–2.83) 0.112 2.31 (2.06–2.72) 2.22 (1.92–2.49) 0.031
P Cr Cl L/day 6.1 (3.8–9.8) 6.2 (4.8–8.1) 0.30 6.1 (4.2–8.1) 5.9 (4.6–8.6) 0.189
U Cr Cl L/day 4.9 (2.9–6.5) 5.2 (4.4–8.9) 0.09 4.5 (2.9–7.2) 3.5 (2.4–6.5) 0.007
T Cr Cl L/wk/1.73m2 76.5 (46.9–142.5) 78.6 (40.6–211.9) 0.86 75.4 (45.3–172.0) 67.1 (42.3–121.3) 0.001
UF 24 hours mL 1350 (−600–2350) 995 (−500–1950) 0.0003 1025 (464–1915) 1185 (0–2385) 0.026
U Volume mL/day 875 (5–3500) 925 (20–3400) 0.22 919 (108–2000) 660 (100–2260) 0.003
Dialysate/plasma Cr 4 hrs 0.59 (0.35–0.8) 0.63 (0.34–0.89) 0.008 0.60 (0.38–0.8) 0.56 (0.42–0.8) 0.0003
Weight kg 70.0 (42.5–103.5) 71.25 (47.0–102.5) 0.066 78.0 (41.0–101.6) 78.0 (42.0–104.4) 0.809
Systolic BP mm Hg 135 (70–190) 130 (70–180) 0.934 130 (85–220) 133 (91–170) 0.668
Diastolic BP mm Hg 80 (50–110) 81 (45–110) 0.929 80 (50–110) 81 (45–110) 0.743
Glucose In g/day 149.78 (105.4–283.32) 155.23 (113.5–336.38) 0.0048 141.08 (124.5–308) 143.55(44.85–308) 0.423
Abbreviations are: P, peritoneal; U, urinary; Cl, clearance; Cr, creatinine; UF = ultrafiltration; T, total. Data are median (range).
Table 3. Dialysis adequacy and peritoneal transport in anuric patients
Group I Group I Group II Group II
SPDF balance balance SPDF
(N = 11) (N = 11) P value (N = 8) (N = 8) P value
Kt/V 2.01 (1.78–2.1) 1.92 (1.67–2.32) 0.893 2.28 (2.04–2.5) 2.19 (1.83–2.33) 0.345
Total Cr Cl L/wk/1.73m2 68.7 (63.5–70.3) 63.7 (62.0–67.5) 0.328 62.9 (58.9–69.4) 63.8 (56.0–66.9) 1.00
D/P Cr 4 hours 0.66 (0.59–0.76) 0.65 (0.55–0.76) 0.790 0.59 (0.58–0.63) 0.57 (0.56–0.59) 0.161
UF 24 hours mL 1623 (525–2350) 1250 (285–1700) 0.182 911 (500–1800) 1202 (473–2395) 0.087
Abbreviations are: SPDF, standard PD fluid; Cl, clearance; Cr, creatinine; UF, ultrafiltration; D/P, dialysate/plasma ratio. Median (interquartile range).
DISCUSSION
The present study has employed a crossover design in
parallel study arms to examine the effects of the switch
(in both directions) in continuous treatment with stan-
dard acidic-lactate PDF or a new neutral pH low GDP
dialysis solution (SPDF to balance in group I and balance
to SPDF in group II). Using this approach, any carry-
over effect is exposed, and the validity of the significant
change can be tested bidirectionally. There may however
be a gradual underlying change over time in certain pa-
rameters, such as residual renal function, which may dis-
advantage one of the groups.
The primary end point of this study was to measure the
difference in CA125 concentration in the peritoneal efflu-
ent when patients were exposed to balance solution or to
SPDF. In both group I and group II patients, the switch
from SPDF to balance resulted in a three- to four-fold
rise in the concentration of CA125. These increases in
dialysate CA125 levels are similar in magnitude to those
previously observed in single arm studies with low GDP
solutions [7], but greater in magnitude than those seen
with a bicarbonate/lactate-buffered solution [8]. Each of
these new fluids has been presented as a more biocom-
patible alternative to its corresponding standard solution,
either with increased or physiologic pH, and each new
solution has significantly reduced levels of GDP [24, 33,
34]. Although it has been argued that CA125 levels re-
flect mesothelial cell mass [35, 36], it remains unclear
why different “more biocompatible” solutions result in
different increases in CA125 appearance rate. While it
is tempting to speculate that this may be directly re-
lated to GDP content, to date there are no experimental
data to support this supposition. The findings of the
present study tend to suggest that CA125 levels are a
measure of mesothelial cell homeostasis because over a
three-month period, mesothelial cell mass is unlikely to
change three- to four-fold, and therefore, the change in
levels likely reflects synthesis by the resident mesothelial
cell population, which are more sensitive to the less bio-
compatible standard fluid. This result also emphasizes the
paucity of knowledge regarding the control of CA125 syn-
thesis, but emphasizes the fact that it can be up-regulated
and down-regulated [37].
Hyaluronic acid (HA) is also a product of mesothelial
cell synthesis and has previously been shown to reflect
intraperitoneal inflammation [38, 39]. Studies with bal-
ance would suggest that HA levels are lower with the
more biocompatible solution, concurring with previous
studies [7, 8]. In the present study, HA levels were signifi-
cantly lower on balance in both group I and group II. This
would suggest that conventional fluid has a proinflamma-
tory effect on mesothelial cells. To suggest that there is a
true inflammatory component active during conventional
dialysis, however, requires evidence that other inflam-
matory markers are also elevated. To examine this we
measured concentrations of VEGF and TNFa in dialysis
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effluent. The concentration of the former is thought to
reflect inflammatory activation of mesothelial cells, and
the latter the activation of peritoneal macrophages [40–
42]. VEGF and TNFa levels did not change when pa-
tients were switched from one fluid to the other. As a
marker of peritoneal membrane turnover, PICP levels
in peritoneal effluent were measured. Previous studies
had shown conflicting results, Rippe et al showing signif-
icantly higher levels, but Jones et al showing no signifi-
cant change [7, 8]. In the present study, PICP levels rose
significantly in the balance-treated group and fell when
they were switched back to conventional fluid. Although
it might be suggested that this molecule, released when
collagen 1 is synthesized, might reflect a tendency to fibro-
sis, it is much more likely to be reflecting an improvement
in peritoneal membrane homeostasis with ‘normalized’
contribution of the mesothelium to extracellular ma-
trix turnover. In this respect, Witowski et al interpreted
the significantly reduced release of PICP from human
peritoneal mesothelial cells exposed to conventional PD
effluent as representing inhibition of cell function [43].
In a subgroup of patients, AGE levels in peritoneal
effluent and in serum were measured. There were no sig-
nificant changes in the concentration of either of CML
and imidazolone in peritoneal effluent, whether on bal-
ance or standard solution, probably because their con-
centrations were so low in the spent dialysate, as has
previously been described [28]. In contrast, serum CML
and imidazolone levels were significantly lower in pa-
tients treated with balance (falling in group I and in-
creasing in group II). This is the first long-term clinical
outcome study providing evidence that the levels of AGE
reflect the composition of infused PD solutions. Balance
has been shown to contain significantly lower levels of
GDP than conventional solutions [24], and these results
support of a direct link between GDP infusion and sys-
temic AGE formation [28]. An alternative explanation
might be that the lower level of RRF demonstrated in
patients using conventional solutions may have resulted
in an accumulation of AGE [44]. In the present study,
however, there was no correlation between changes in
AGE levels and changes in renal function.
Measurement of peritoneal function, RRF, and dialy-
sis adequacy in such a large group of patients, and in a
study with a crossover design, has allowed us to exam-
ine the impact of a fluid containing low levels of GDP
in direct comparison with a standard solution. The pres-
ence of parallel arms in the study design also enabled
us to identify whether there was a temporal difference
in any recovery of physiology when switching to balance
compared with any change in function when switching to
standard solution.
When the study population was analyzed, renal cre-
atinine clearance was higher when the patients were
on balance than when they were on standard solution.
Peritoneal creatinine clearance did not change. The mag-
nitude of change of total creatinine clearance was, how-
ever, different between the groups. In group I there was a
small but not significant rise when patients were switched
from conventional to balance solution in contrast to the
expected fall in creatinine clearance with time on PD
[45, 46]. In group II there was a significant fall in cre-
atinine clearance when the patients switched from bal-
ance to conventional fluid. Although these data may be
confounded by the impact of changes in residual vol-
ume on the measurement of urinary creatinine clearance,
the overall data are nevertheless indicative of improved
RRF in patients treated with balance.
Urine urea clearances were significantly higher on bal-
ance in both groups, whereas peritoneal urea clearance
remained unchanged. When these clearances were com-
bined and expressed as Kt/V, there was again a differ-
ence in the magnitude of change between the groups. In
group I there was a nonsignificant rise in Kt/V when
balance was introduced, but in group II there was a sig-
nificant fall when the patients were switched back to con-
ventional fluid.
The changes in renal function (increased clearances
and increased volume) when patients were on balance
solution were accompanied by an increase in D/P creati-
nine and a decrease in peritoneal UF in both groups. It
is impossible, however, from the structure of the present
study, to determine whether or how these changes are
linked. As a result, only cautious interpretation of the
results can be made. In terms of overall fluid balance,
the decrease in peritoneal ultrafiltration in patients using
balance was matched by the relative increase in urine vol-
ume. Although signs suggestive of overhydration, such as
increased body weight, changes in blood pressure, and
an increased number of antihypertensive agents were
not seen, it is still possible that the observed changes
were related to a higher extracellular volume in balance-
treated patients. Additional studies to specifically ad-
dress the mechanism of these observed effects are clearly
warranted.
Individual dialysis prescriptions were not standard-
ized for patients in the study, and as such, changes in
glucose prescription were the prerogative of individual
physicians. Glucose prescription increased significantly
in group I patients when comparing the end of visit 3 to
the end of visit 2, presumably as a response to an observed
decrease in ultrafiltration volume. No change in glucose
prescription could be demonstrated in group II patients.
It may be that the increase in small-molecular-weight
transport represented by D/P creatinine is a reflec-
tion of increased peritoneal permeability caused by
increased peritoneal vascular surface area and/or
mesothelial surface area. An increase of peritoneal vas-
cular flow, whether functional (more perfusion of existing
vessels) or related to neoangiogenesis, appears unlikely,
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particularly because animal studies with balance and
standard solutions suggest that, in contrast to standard
acidic PD fluid, balance provoked only minor changes
in the peritoneal vasculature [22, 47]. A more likely ex-
planation is that altered mesothelial cell function could
influence solute transport by increased production of va-
soactive substances, which might significantly influence
both blood flow and the permeability of the peritoneal
vascular bed [12, 48].
Subgroup analysis of the anuric patients failed to show
significant changes in membrane function, although there
was a tendency for ultrafiltration to fall in the balance-
treated group. Membrane function, as assessed by D/P
creatinine, did not show any consistent change in the
anuric group. This subgroup analysis, however, involved
small numbers of patients, and was therefore likely to give
rise to type 2 statistical errors. A more detailed study to
examine the effects of such solutions on membrane func-
tion is clearly warranted.
The present study clearly demonstrates that the com-
position of the dialysis fluid is capable of having an impact
on the dialytic capacity of the peritoneal membrane and
on renal function. It may be that the new fluid has an im-
pact on the peritoneal membrane, resulting in higher so-
lute transport, decreased UF, which results in increased
circulatory volume, and higher renal blood flow. How-
ever, because no signs of overhydration were seen in pa-
tients treated with balance, it might be that the changes to
peritoneal membrane UF and renal output occurred in-
dependently. Although the composition of the low GDP
solution is potentially responsible for the observed better
preservation of kidney function, it is also possible that yet
unknown hemodynamic effects contribute to this process.
Significant changes in residual renal function have not
been previously reported in clinical trials of new solu-
tions [7, 49, 50]. Changes in ultrafiltration, however, have
shown inconsistent results, with small increases [50] or no
significant change being observed [7, 49]. The differences
between these previous studies and the current one lie in
the design of the study, where each patient acts as his or
her own control, allowing for a more powerful analyti-
cal approach. Having a bidirectional crossover in the two
arms may also reveal differences between the solutions
that might not be seen in a standard two-group compari-
son. A comparison of the magnitude of change between
group I and II also yields interesting results. In group I,
patients switched from standard solution to balance, and
in group II they switched from balance to standard. A
review of Table 2 shows that the magnitude of change
was almost always greater in group II. This suggests that
there is an impact of standard solution on RRF, whereas
there is none when balance is introduced. In group I there
was the same trend in the change, but this only reached
significance in a few instances. Presumably, there is a car-
ryover effect when patients are exposed to the conven-
tional solution for longer periods, as in group I, which may
have lasted for more than the three months allowed for
equilibration in this study.
Previous studies have suggested significantly reduced
infusion pain in susceptible individuals using more bio-
compatible solutions [51]. The presence of inflow pain
was specifically measured in this study using an analog
scale. No differences could be demonstrated between the
groups. The overall pain levels in the group exposed to
conventional fluid, however, were small. This may ac-
count for the lack of benefit of the neutral pH, low GDP
solution.
The study was powered to examine in detail the bi-
ological parameters, principally CA125, in the effluent.
The clinical findings were unexpected, but raise a num-
ber of important questions regarding our understanding
of the effects of PD solutions on peritoneal and/or renal
function. The perceived wisdom of ‘normality’ is based on
our long-term experience with conventional solutions. As
we introduce newer, more biocompatible solutions, there
will be a need to re-evaluate our concept of what is ‘nor-
mal and abnormal,’ and carry out more detailed studies
using functional end points. The time course of changes
observed in the markers of peritoneal biology may well
precede the clinical changes that develop over years on
PD. Based on the evidence presented in this paper, a
longer clinically based outcome study is required, with
further consideration given to chosen end points such as
comorbidity, hospitalization, and quality of life [52–56].
CONCLUSION
We have demonstrated that a new PD solution deliv-
ered to the peritoneum at neutral pH, and containing sig-
nificantly lower levels of GDP, may significantly improve
the homeostasis of the peritoneal cavity. A reduction in
circulating reactive carbonyl compounds is suggestive of
a potential systemic benefit of balance. Finally, changes
in the composition of fluid, not surprisingly, may have an
effect on the dialytic capacity of the patient. A possible
higher RRF in patients on balance may be beneficial to
the patient in the long term. The observation that the dif-
ferences in renal function on balance are accompanied by
changes in peritoneal function (higher D/P creatinine) re-
quires a more detailed study. In the anuric patient, how-
ever, it appears to have a neutral effect on peritoneal
function, and its dialytic parameters are identical to stan-
dard solution.
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